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Edited by Takashi GojoboriAbstract This study investigates for the ﬁrst time the dynamics
of endocannabinoid system appearance during low vertebrate
Xenopus laevis development. We observed that the CB1 gene
started to be expressed during the organogenesis period
(±1 dpf, st. 28) and expression persisted throughout the three
further stages analyzed. Attention was focused on the localiza-
tion of the CB1 messenger that was found both at the central le-
vel (in romboencephalon and in olfactory placods) and at the
peripheral level (in the gastrointestinal tract) at ±3 dpf (st. 41),
±4 dpf (st. 46) and ±12 dpf (st. 49). We also considered the syn-
thesis of CB1 protein that occurred from st. 41 onwards and,
from this stage, we tested the receptor functionality in response
to anandamide using cytosensor microphysiometry. CB1 func-
tionality increased with development at both central and periph-
eral level. These data provide suﬃcient evidence to encourage
further analysis on endocannabinoid physiological roles during
embryonic and larval X. laevis growth.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Anandamide1. Introduction
Cannabinoid receptor CB1 was ﬁrst characterized in 1988 [1]
and cloned in 1990 [2]. To date, most studies have been per-
formed on mammals where CB1 was found to be densely pres-
ent, at central nervous system (CNS) level, in several brain
areas [3]. CB1 has also been detected in sensory neurons of
the dorsal root ganglia of the peripheral nervous system [4],
in the liver and in the gut [5,6].
The identiﬁcation of an endogenous cannabinoid ligand,
anandamide [7], contributed to understanding the functions
of the endocannabinoid system by evidencing its important
role in synaptic regulation. This system is involved in many
physiological functions, such as pain control [8], cognition [9]
and reproduction [10,11]. Moreover the CB1 receptor is in-
volved in water and food intake [12,13] and regulates lipid
metabolism at peripheral level [6].
Cannabinoids stimulate food intake by activating the CB1
receptor in the hypothalamus [14] and also mediate satiety sig-*Corresponding author. Fax: +39 071 2204650.
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also evidence of the involvement of CB1 in food ‘‘liking’’
[17,18]: CB1 agonist administration seems to stimulate the in-
take of sweet food.
At the hepatic level, it has also been demonstrated that hepa-
tocytes express CB1 inducing the expression of enzymes in-
volved in lipid metabolism and de novo fatty acid synthesis [6].
In non-mammalian animals the involvement of CB1 in food
intake has been studied in Carassius auratus [19], but nothing is
known about the endocannabinoid system during embryo
development and its role in ﬁrst feeding.
This study aimed to show the appearance and the function-
ality of the endocannabinoid system during the growth of a
lower vertebrate. Xenopus laevis was chosen as an experimental
model because of the wide knowledge of its developmental
biology and because ‘‘amphibian has found to represent key
group in CB1 evolution through vertebrates’’ [20,21].2. Materials and methods
2.1. Animals maintenance and reproduction
X. laevis embryos were generated using standard methods [22]. Em-
bryos and larvae obtained were staged according to Nieuwkoop and
Faber’s tables [23]. For the analysis the following developmental stages
were selected: early gastrula stage, 9 hpf (st. 10), late organogenesis
stage, ±1 dpf (st. 28), yolk sack absorption stage, ±3 dpf (st. 41), ﬁrst
hindlimb bud stage, ±4 dpf (st. 46), advanced larval stage, ±12 dpf
(st. 49).
2.2. RNA extraction and analysis of CB1 gene expression by RT-PCR
Total RNA was extracted from stages 10, 28, 41, 46, 49 and from
whole adult brain, used as positive control, with RNeasy Mini Kit
(250) (Quiagen) and ﬁrst strand cDNA synthesis was performed as
already described in [24]. cDNA was ampliﬁed with 5 U of Taq
DNA polymerase (Dynazyme) in 20 ll of total volume containing
1· PCR buﬀer, 1.5 mM MgCl2, 2.5 mM dNTPs, and primers
(FCB1: 5 0-TCCTACCACTTCATTGGCAGCTT-3 0, RCB1: 5 0-
TCCATGCG(AT)G(CT)CTGGTCC-30). CB1 ampliﬁcation was car-
ried out with the following proﬁle: 5 min at 94 C, 30 cycles at 94 C
for 1 min, 55 C for 1 min, and 72 C for 1 min. In order to semi-
quantify the CB1 gene expression, b-actin was used as internal stan-
dard (Fb-actin: 5 0-TTCCTCGGTATGGAGTCCT-3 0, Rb-actin: 5 0-
TGGGGCAATGATCTTGATCTT-3 0) using the following proﬁle:
20 s at 94 C, primer annealing at 56 C for 30 s and primer exten-
sion at 72 C for 30 s.
2.3. CB1 cloning and sequencing
The PCR product obtained with CB1 speciﬁc primers was puriﬁed
using the PCR puriﬁcation kit (QIAGEN) and then cloned into the
p-GEM T easy vector (Promega), following the manufacturer’s
protocol. The plasmid was transformed into DH5a cells by theblished by Elsevier B.V. All rights reserved.
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analyzed by PCR, in order to verify the presence of the insert. Only
the clones showing CB1 insert were then grown in liquid broth with
ampicillin (1:1000 in LB broth). The insert was then sequenced using
an ABI model 310 DNA sequencer (Perkin–Elmer, Oak Brook, IL,
USA).
2.4. cRNA probes synthesis
The antisense cRNA probe for CB1 was generated by linearizing the
vector with NcoI and transcribing the template using SP6 polymerase.
The sense probe was synthesized by using of PstI as restriction enzyme
and T7 as polymerase.
2.5. Whole-mount in situ hybridization
The whole mount in situ hybridization let to analyze the localization
of CB1 mRNA in all the developmental stages where CB1 gene was
evidenced by RT-PCR. Embryos or larvae from each stage mentioned
before were ﬁxed in 4% paraformaldehyde during 24 h at 4 C, then
rinsed with serial concentrations of methanol and PBT (25%, 50%,
75% and 100% MeOH) and stored at 20 C.
Prehybridization, hybridization, washing and detection procedures
were conducted according to Roche protocols except for the ﬁnal
staining reaction which was not applied [25]. Negative controls were
performed using the antisense probe preadsorbed with the sense
probe in excess (200/400 lg/ll). Autoﬂorescence was analyzed in all
developmental stages. Images were obtained by Confocal Micros-
copy.
2.6. Western blot analysis
To study the presence of CB1 receptor, embryos and larvae samples
were homogenised and treated as described by Tsou et al. [26]. CB1
was detected with the antibody [anti-cannabinoid receptor CB1, Rat
(Rabbit) Calbiochem] diluted 1:1000.
2.7. Cell preparation and functional assay by cytosensor
microphysiometry
The activation of CB1 receptor was assessed in whole embryos and
larvae in st. 41, st. 46 and st. 49, where the presence of CB1 protein was
demonstrated by Western blot. X. laevis embryos and larvae were ana-
lyzed in toto and with head and trunk separately. Cells were isolated
by mechanical dissociation and ﬁltration through nylon mesh
(40 lm) to remove cellular aggregates and then centrifuged, washed
and resuspended in Dulbecco’s modiﬁed Eagle’s medium 4500 mg/ml
glucose supplemented with 10% fetal calf serum, 100 U/ml penicillin,
and 100 lg/ml streptomycin. The stimulation with CB1 agonist,
(Anandamide, (AEA) Calbiochem) and antagonist (AM 251, Cayman,
[27]) dissolved in DMSO (102 M as stock solutions), and the acidiﬁ-
cation rate analysis performed by cytosensor microphysiometry were
conducted as already described by Pihlavisto and Scheinin [28] and
Gentili et al. [29].2.8. Statistical analysis
Values of pEC50 and the extent of maximal response (Emax) were
calculated from the dose response curves using the program GraphPad
Prism (Graph-Pad Software, San Diego, CA). The results are ex-
pressed as means SEM of three separated experiments.Fig. 1. Temporal CB1 gene expression during X. laevis development. b-Actin
and negative controls, respectively.3. Results and discussion
At CNS level, the involvement of the endocannabinoid sys-
tem in several pathways is quite well known [30,21]. Currently
there is a lot of interest in CB1 peripheral pathways, especially
concerning food intake and metabolism. This study aims to
provide basic evidence on CB1 receptor dynamics during
amphibian development both at central and peripheral levels.
3.1. CB1 appearance during X. laevis development
In the ﬁrst stage (st. 10) analyzed by RT-PCR (Fig. 1) and
Western blot (Fig. 3), there was no trace of CB1 receptor
mRNA expression and protein synthesis, thus suggesting that
the endocannabinoid system is not involved in biological pro-
cesses until the gastrula period.
CB1 mRNA expression was ﬁrst detected in the whole em-
bryos at st. 28 (Fig. 1), but at a very low level. The ampliﬁca-
tion provided a single band of 603 bp corresponding to the
brain CB1 previously sequenced and used as positive control.
The localization of CB1 mRNA was not possible because of
the high autoﬂuorescence of the sample that did not allow
the signal of the messenger to be recognised (Fig. 2,a 0, a00
and a000).
Western blot analysis demonstrated that in the latter stage
mentioned (st. 28) the expression of the CB1 gene was not fol-
lowed by synthesis of the protein: no reaction with CB1 anti-
body was observed (Fig. 3).
CB1 mRNA expression (Fig. 1), protein synthesis (Fig. 3) as
well as the activation of the receptor by AEA (Fig. 4) were ﬁrst
observed at st. 41 in whole embryos and larvae. The protein
detected by Western blot was 63 kDa, the same as the CB1 de-
tected in the adult Xenopus brain which was used as positive
control. This size also corresponds to CB1 described in the
rat [26] (Fig. 3).
The same evidence found at st. 41 persisted in st. 46 and st.
49 (Figs. 1–4), with an increase in both mRNA expression and
CB1 receptor aﬃnity to AEA during development (Table 1).
These data induced us to focus the attention on central and
peripheral CB1 dynamics separately in order to determine
CB1 functionality at both central and peripheral levels.
3.2. CB1 at CNS level
Using whole mount in situ hybridization it was possible to
localize the CB1 mRNA, previously detected by RT-PCR in
whole embryos and larvae.
Three days after fertilization (st. 41) CB1 mRNA appeared
in the romboencephalon (Fig. 2b 0), where it was also found
in adults [21].was used as internal standard. Brain and water were used as positive
Fig. 2. CB1 mRNA localization detected by whole mount in situ hybridization. Stainings in green indicate CB1 expression or samples
autoﬂuorescence. (a) Lateral view of stage 28. (a 0) The signal is not speciﬁc: the same ﬂuorescent evidences are detectable in (a00). (b) Lateral view of
stage 41. (b 0) Evidences of CB1 expression at romboencephalon and digestive tract levels. (b00) Very low autoﬂuorescence signal. (c) Dorsal view of
stage 46. (c 0) CB1 expression, from the top, at olfactory placodes, romboencephalon, digestive tract and spinal cord levels. (c00) Very low
autoﬂuorescence. (d) Dorsal view of stage 49. (d 0) Evidences of CB1 mRNA localization in olfactory placodes and romboencephalon areas, in the
head, and in digestive tract and spinal cord, in the trunk. (d00) No evidence of autoﬂuorescence. (a000,b000,c000,d000) Negative control performed with
antisense probe preadsorbed with the sense probe in excess.
Fig. 3. Western blot analysis demonstrates the increase of CB1 receptor synthesis during X. laevis development. Brain has been used as positive
control. The band corresponds to 63 kDa.
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romboencephalon and appeared in olfactory placodes
(Fig. 2c 0). This ﬁnding is supported by Buckley et al. [31],who showed the same localization in rat embryos, and by sim-
ilar ﬁndings in adult X. laevis brain [21] and in adult rat brain
[32].
Fig. 4. Concentration–response curves generated from the extracellu-
lar acidiﬁcation rate data. The responses relative to AEA exposure
were calculated in whole animal, head and trunk of stages 41, 46 and
49. Data points with error bars represent the means ± S.E.M. of 3–6
separate experiments.
Table 1
pEc50 values in whole animal, head and trunk detected by cytosensor
microphysiometry
pEc50 Whole Head Trunk
Stage 41 6.02 6.47 4.88
Stage 46 6.31 6.75 5.33
Stage 49 6.58 7.12 5.76
1944 M. Beatrice et al. / FEBS Letters 580 (2006) 1941–1945In the last stage studied (st. 49), because of the fusion of the
olfactory bulbs, the presence of the CB1 was more concen-
trated than in the romboencephalon area (Fig. 2d 0).
The functional analysis performed in the head showed an
increasing CB1 aﬃnity for AEA during development, indicat-
ing that the speciﬁcity of the endocannabinoid system grows
with the complexity of the organism. In particular, in the
stages analyzed in this study, these data could be due to the
ﬁrst feeding period (st. 41 and st. 46), when the appetite starts
to be stimulated at CNS level because of yolk sack absorption
[23]. CB1 is known to be involved in this kind of physiological
mechanism in mammals: it is involved in suckling activity [32].
Such a hypothesis should however be conﬁrmed through fur-
ther speciﬁc analysis on the experimental model studied here.
3.3. CB1 presence and functionality at peripheral level
It was interesting to observe what occurred at peripheral le-
vel during development. After st. 41, the yolk sack is com-
pletely absorbed [23], involving many physiological changes
regarding ﬁrst feeding and food metabolism.
The appearance of CB1 mRNA at st. 41 (Fig. 1) and its
localization in the digestive tract (Fig. 2b 0) were supported
by the functionality assay performed with AEA on the trunk
of the larvae (Fig. 4). CB1 was already active at st. 41
(Fig. 4), thus suggesting that the endocannabinoid system
starts to work when the yolk sack is completely re-absorbed
and the larvae start to feed. The yolk sack contains proteins,
lipids and enzymes as lipases: its disappearance provokes sev-
eral physiological changes.
Food ﬁrst appears in the intestinal tract at st. 46 [23]; larvae
start to eat on their own andmetabolic processes are in progress.
In this study, at st. 46 and st. 49, the presence ofCB1mRNAper-
sisted in the digestive tract (Fig. 2c 0 and d 0) suggesting its possi-
ble involvement in lipid metabolism by increasing lipoprotein
lipase activity, as described by Cota in mammals [12]. The func-
tionality analysis performed on the trunk showed that, at this
stage,CB1 aﬃnity forAEAwashigher than at the previous stage
(Fig. 4), suggesting that theCB1 lipase pathway could ﬁll the gap
arising from yolk sack absorption. All these hypotheses need
further investigation. The possible involvement of CB1 in such
biological processes, underlines the possibility of investigating
items previously studied only in mammals.
This study provides a clear picture of endocannabinoid sys-
tem localization and functionality at central and peripheral le-
vel during X. laevis development.
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